New compound disrupts receptor complex to block hepatitis B and D viruses
The compound Oxy229 selectively inhibits HBV and HDV infection in specific cells.
Hepatitis B virus (HBV) and hepatitis D virus (HDV) enter hepatocytes through a coordinated process. This process uses a receptor complex made of sodium taurocholate cotransporting polypeptide (NTCP) and host entry cofactors like epidermal growth factor receptor (EGFR).
Researchers established an in vitro assay to evaluate the NTCP-EGFR interaction. They identified Oxy229, an oxysterol-based compound, which disrupted this molecular interaction. Oxy229 selectively inhibited HBV and HDV infection to HepG2-NTCP cells and primary human hepatocytes.
Mechanistic analysis showed Oxy229 impaired the relocalization of the HBV-NTCP complex from the plasma membrane to intracellular vesicles. The compound did not compromise the physiological functions of NTCP or EGFR. These functions include bile acid transporter activity and activation of downstream EGFR signaling pathways including Ras-MAPK and PI3K-Akt pathways.
A derivative called Oxy283 was identified through compound derivative analysis. Oxy283 acquired dual inhibitory activity against both the NTCP-EGFR interaction and NTCP multimerization. This resulted in enhanced anti-HBV potency.
These findings highlight the NTCP-EGFR receptor complex formation as a potential target for antiviral intervention. The functional significance of the complex in HBV/HDV entry is established.
Key facts
- Oxy229 disrupts the NTCP-EGFR interaction to selectively inhibit HBV and HDV infection.
- Oxy229 does not compromise bile acid transporter functions or downstream EGFR signaling pathways.
- Oxy283 provides dual inhibitory activity against the NTCP-EGFR interaction and NTCP multimerization.